Low Dose Cyclosporin A in Primary Sjögren Syndrome (CYPRESS)
Primary Purpose
Sjögren´s Syndrome
Status
Completed
Phase
Phase 2
Locations
Germany
Study Type
Interventional
Intervention
Cyclosporine A
Sponsored by

About this trial
This is an interventional treatment trial for Sjögren´s Syndrome focused on measuring primary Sjogren´s Syndrome, Cyclosporine
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of a primary Sjögren´s Syndrome
- Liver values above 1,5 ULN
- uncontrolled arterial hypertension
- intraarticular or systemic use of Glucocorticoids in the last 4 weeks before
- begin with Study medication
Exclusion Criteria:
- pre-treatment with Cyclosporine A
- Infection
- Neoplasia
- relevant cardiac, pulmonary, neurologic or psychiatric disease
- life-Vaccination within 4 weeks before begin with study medication
- pregnant or breast-feeding
- weight under 45kg or more than 110kg
Sites / Locations
- Charite Universitätsklinikum Berlin Campus Mitte
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Cyclosporine A
Arm Description
All patients will receive Cyclosporine A in a dose of 2mg/kg/BW daily for 16 weeks
Outcomes
Primary Outcome Measures
Examination of the therapeutic effects (improvement in number of tender, swolen joints, DAS 28) of low dose Cyclosporine A in patients with primary Sjögren Syndrome and articular involvement after a treatment-phase of 16 weeks.
Secondary Outcome Measures
Evaluation of the safety (type and number of adverse events and serious adverse events) of low-dose Cyclosporine A in patients with primary Sjögren Syndrome
Full Information
NCT ID
NCT01693393
First Posted
September 14, 2012
Last Updated
July 27, 2015
Sponsor
Charite University, Berlin, Germany
1. Study Identification
Unique Protocol Identification Number
NCT01693393
Brief Title
Low Dose Cyclosporin A in Primary Sjögren Syndrome
Acronym
CYPRESS
Official Title
A Phase II Pilot-Study With Low-dose Sandimmun Optoral (Cyclosporin A) for the Treatment of Primary Sjögren Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
July 2015
Overall Recruitment Status
Completed
Study Start Date
March 2010 (undefined)
Primary Completion Date
October 2014 (Actual)
Study Completion Date
October 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Charite University, Berlin, Germany
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Sandimmun optoral (Cyclosporin A) is used for the musculoskeletal manifestations of Primary Sjögren Syndrome
Detailed Description
NSAR are used currently for the treatment of musculoskeletal manifestations at Sjögren Syndrome for the symptomatic release of pain. For therapy-resistant cases drugs also used in Rheumatoid Arthritis are used. For these drugs there is no registration for the treatment of Sjögren Syndrome.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sjögren´s Syndrome
Keywords
primary Sjogren´s Syndrome, Cyclosporine
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Cyclosporine A
Arm Type
Other
Arm Description
All patients will receive Cyclosporine A in a dose of 2mg/kg/BW daily for 16 weeks
Intervention Type
Drug
Intervention Name(s)
Cyclosporine A
Other Intervention Name(s)
Sandimmun optoral
Intervention Description
Patients will receive Cyclosporine A in a dose of ca. 2mg/kg/BW daily for a 16 week period
Primary Outcome Measure Information:
Title
Examination of the therapeutic effects (improvement in number of tender, swolen joints, DAS 28) of low dose Cyclosporine A in patients with primary Sjögren Syndrome and articular involvement after a treatment-phase of 16 weeks.
Time Frame
16 weeks
Secondary Outcome Measure Information:
Title
Evaluation of the safety (type and number of adverse events and serious adverse events) of low-dose Cyclosporine A in patients with primary Sjögren Syndrome
Time Frame
28 weeks
Other Pre-specified Outcome Measures:
Title
Study the general health changes and improvement of Sicca-symptoms
Time Frame
16 weeks
Title
Documentation of improvement of articular manifestations by ultrasound examination
Time Frame
16 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of a primary Sjögren´s Syndrome
Liver values above 1,5 ULN
uncontrolled arterial hypertension
intraarticular or systemic use of Glucocorticoids in the last 4 weeks before
begin with Study medication
Exclusion Criteria:
pre-treatment with Cyclosporine A
Infection
Neoplasia
relevant cardiac, pulmonary, neurologic or psychiatric disease
life-Vaccination within 4 weeks before begin with study medication
pregnant or breast-feeding
weight under 45kg or more than 110kg
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eugen Feist, Dr. med.
Organizational Affiliation
Charite University, Berlin, Germany
Official's Role
Principal Investigator
Facility Information:
Facility Name
Charite Universitätsklinikum Berlin Campus Mitte
City
Berlin
ZIP/Postal Code
10117
Country
Germany
12. IPD Sharing Statement
Citations:
PubMed Identifier
27470087
Citation
Kedor C, Zernicke J, Hagemann A, Gamboa LM, Callhoff J, Burmester GR, Feist E. A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sjogren's syndrome. Clin Rheumatol. 2016 Sep;35(9):2203-10. doi: 10.1007/s10067-016-3360-4. Epub 2016 Jul 28.
Results Reference
derived
Learn more about this trial
Low Dose Cyclosporin A in Primary Sjögren Syndrome
We'll reach out to this number within 24 hrs